Modified FOLFOX-6 Chemotherapy for Recurrent or Inoperable Gastric Cancer Patients
Journal of the Korean Gastric Cancer Association
;
: 40-46, 2008.
Artigo
em Coreano
| WPRIM
| ID: wpr-82873
ABSTRACT
PURPOSE:
We wanted to evaluate the efficacy and toxicity of modified FOLFOX-6 chemotherapy for treating recurrent or inoperable gastric cancer patients. MATERIALS ANDMETHODS:
From April 2006 to August 2007, 35 patients with recurrent gastric cancer after curative resection and 43 patients with inoperable gastric cancer underwent chemotherapy, and the results were retrospectively investigated.RESULTS:
78 patients were assessable for response and toxicity, and they underwent an average of 7.1 cycles of chemotherapy. The response was evaluated according to the RECIST criteria. 11 partial responses (14.1%), 35 cases of stable disease (44.9%), and 32 cases of progressive disease (41%) were observed. The median time to progression was 6 months, and the average overall survival was 13 months. CTCAE grade 1 or 2 anemia (52.6%) was the most prevalent toxicity. Other common toxicities included thrombocytopenia (17.9%) and peripheral neuropathy (30.8%). There were 13 changes in the chemotherapy regimen to S1-cisplatin due to disease progression, but only an average of 1.76 cycles of S1-cisplatin were delivered due to severe toxicities and poor compliance.CONCLUSION:
Acceptable efficacy and toxicity were seen as 59% of the patients showed non-progression, and no grade 3 or 4 toxicities were observed. In conclusion, the modified FOLFOX-6 chemotherapy is considered to be the proper 1st-line choice as a palliative treatment for recurrent or inoperable gastric cancer patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos Organoplatínicos
/
Cuidados Paliativos
/
Neoplasias Gástricas
/
Trombocitopenia
/
Estudos Retrospectivos
/
Doenças do Sistema Nervoso Periférico
/
Progressão da Doença
/
Anemia
Tipo de estudo:
Estudo observacional
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Gastric Cancer Association
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS